Изучение фармакокинетики нового отечественного препарата содержащего клопидогрел
Диссертация
Наряду с тиклопедином (другой препарат с аналогичным механизмом действия) клопидогрел широко применяется для профилактики тромбов, однако по сравнению с тиклопедином клопидогрел более безопасен. Оба эти препарата по крайней мере столь же эффективны для профилактики тромбоза, как и аспирин или превосходят последний по способности снижать степень комбинированного риска инфаркта миокарда, сосудистой… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- Глава 1. ЛИТЕРАТУРНЫЙ ОБЗОР
- 1. 1. Тиклопидин и клопидогрел — тиенопиридины разных поколений
- 1. 2. Клопидогрел против ацетилсалициловой кислоты: исследование САРМЕ
- 1. 3. Фармакокинетика клопидогрела
- 1. 4. Оценка активности изофермента цитохрома
- 1. 5. Методы оценки активности СУРЗА
- 1. 6. Взаимодействие клопидогрела и статинов на уровне СУРЗА
- Глава 2. МАТЕРИАЛЫ И МЕТОДЫ ИССЛЕДОВАНИЯ
- 2. 1. Препараты, средства измерений, вспомогательные устройства
- 2. 2. Реактивы и их приготовление
- 2. 3. Выбор добровольцев
- 2. 4. Проведение исследования
- 2. 5. Расчет фармакокинетических параметров
- 2. 6. Оценка фармакокинетики и клинической эффективности Зилта и Аториса
- 2. 7. Определение концентрации МЕОХ методом ВЭЖХ
- 2. 8. Статистическая обработка результатов
- Глава 3. РЕЗУЛЬТАТЫ СОБСТВЕННЫХ ИСЛЕДОВАНИЙ
- 3. 1. Количественное определение клопидогрела в плазме крови
- 3. 2. Изучение фармакокинетики клопидогрела после однократного приема внутрь
- 3. 3. Количественное определение клопидогрел кислоты в плазме крови
- 3. 4. Изучение фармакокинетики клопидогрел кислоты после однократного приема внутрь
- 3. 5. Сравнительное фармакокинетическое исследование биоэквивалентности препаратов Клорель и Плавике
- 3. 6. Взаимодействие клопидогрела и аторвастатина у больных ИБС
Список литературы
- Аверков O.A. Тиклопидин и клопидогрел — есть ли поводы для противостояния? //Клин, фармак. и терап. — 2007. — Т. 33, № !. — С.33−40.
- Агафонов A.A., Пиотровский В. К. Программа M-IND оценки системных параметров фармакокинетики модельно-независимым методом статистических моментов//Хим-фарм.журнал — 1991. № 10. — С. 16−19.
- Баранов B.C., Баранова Е. В., Иващенко Т. Э., Асеев М. В. Геном человека и гены «предрасположенности». Введение в предиктивную медицину .//СПб.: Интермедика.- 200.-272 с.
- Безверхая И.С. Фармакокинетика при старении. — Киев: Здоровье, 1991. -168с.
- Дупляков Д.В. Клопидогрел и статины, или еще раз об опасности прямого переноса результатов экспериментальных исследований в клиническую практику //Кардиология. 2008. — Т.48, № 2. — С.65−66.
- Жердев В.П., Литвин A.A. Роль и организация фармакокинетических исследований // Клиническая фармакокинетика. — 2005. № 2(3). — С. 1−3.
- Кашаева О.В. Состояние метаболической функции печени и оптимизация фармакотерапии у больных хронической сердечной недостаточностью.//Автореферат. дис.канд.мед.наук. — М. — 2002. — 19 с.
- Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты.//М.:Издательство «Рефарм» — 2004. -186 с.
- Кукес В.Г., Сычев Д. А., Ших Е.В. Изучение биотрансформации лекарственных средств путь к повышению эффективности и безопасности фармакотерапии.//Врач. — 2007. — № 1. — С. 6−8.
- Ю.Мирошниченко И. И. Основы фармакокинетики. М.: Изд.д. «Геотар-мед», 2002. — 186с.
- П.Мирошниченко И. И., Тюляев И. И., Зуев А. П. Биодоступность лекарственных средств — М.: «Грамотей», 2003.-101с.
- Моисеев C.B. Перспективы антитромбоцитарной терапии //Клиническая фармакология и терапия. 2003. — Т.12, № 4ю — С.18−22.
- З.Парфенов В. А. Лечение и профилактика ишемического инсульта//Соп8Шиш Medicum. 2002 г. Т. 4, № 2.
- Преображенский Д.С., Сидоренко Б. А., Батыралиев Т. А. Тиенопиридины в лечении и профилактике сердечно-сосудистых заболеваний. Часть II. Клиническая фармакология клопидогрела //Кардиология. 2009. — Т.49, № 10. — С. 88−96.
- Применение MEGX-теста для оценки активности изофермента цитохрома Р-450 ЗФ4: Методические рекомендации / В. Г. Кукес, Г. В. Раменская, А. А. Игонин и др. М.: ООО КПСФ «Спецстройсервис-92», 2004. — 22с.
- Проведение качественных исследований биоэквивалентности лекарственных средств.// Метод.указания. 2004.
- Раменская Г. В. Хроматографическое определение лекарственных средств и их метаболитов для фенотипирования изоферментов цитохрома Р-450.//Химико-фармацевтический журнал: научно-технический и производственный журнал. 2005. — Том 39,№ 2. — С. 53−56.
- Раменская Г. В., Светый Л. И., Кулинченко A.A. Влияние флуконазола на концентрацию блокаторов медленных кальциевых каналов в плазме крови.// Клиническая фармакология и терапия. 2002. — № 5. — С. 54−56.
- Руксин В.В. Тромбозы в кардиологической практике. СПб.: Невский диалект, М.: Бином, 1998. — 126с.
- Серебряный В.Л., Малинин А. И., Макаров Л. М. Резистентность к клопидогрелу: миф или реальность? //Кардиология — 2007. Т.47, № 10. — С. 69−72.
- Соколов Ф.В. Правила исследования биоэквивалентности лекарств.// Клиническая фармакокинетика. 2004. — № 1. — С. 5−13.
- Страчунский JI.C., Фирсов А. А., Белоусов Ю. Б. и др. Правила проведения биоэквивалентности лекарственных средств. //М. 1995. ч.2. — 16с.
- Сычев Д.А., Раменская Г. В., Игнатьев И. В., Кукес В. Г. Клиническая фармакогенетика./Под редакцией Кукеса В. Г., Бочкова Н.П.//М.:Гэотар-медиа. 2007. — 248с.
- Abbracchio М.Р., Burnstock G. Purinoreceptors: are there families of P2X and P2Y purinoreceptors? // Pharmacol Ther. 1994.- № 64-P.445−475.
- Aspinal M.G., Hamermesh R.G. Realizing the promise of personalized medicine.//Harv Bus Rev. 2007. — 85(10). P. 108−117, 165.
- Ayalasomayajula S.P., Vaidyanathan S., Kemp C. et all. Effects of clopidogrel on the steady state pharmacokinetics of fluvastatin//Journal of Clinical Pharmacology. 2007.-47. — P. 613−619.
- Bahrami G., Mohammadi B. and Sisakhtnezhad S. High performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: Application to a bioequivalence study.//J.Chromatogr.-2008.-V.864.-P. 168−172.
- Beitelshees A.L., McLead H.L. Clopidogrel pharmacokinetics, promising steps toward patientt care? //Arterioscler Thromb. 2006. — V. 26. — P. 1681−1683.
- Belal F., El-Brashy A., Eid M. and Nasr J.J. Stability-Indicating Micellar Liquid Chromatographic Method for the Determination of Clopidogrel/
- Application to Tablets and Content Uniformity Testing.//J.of Liquid Chromatog. — 2009. V.32, № 20. — P.2993−3008.
- Benedetti M. S, Whomsley R., Canning M. Drug metabolism in the paediatric population and in the elderly.//Drug Discovery Today. 2007. -12(15−16).- P.599−610.
- Bennett C., Weinberg P., Rozenberg-Ben-Dror K. et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases.// Ann Intern Med. 1998. — V. 128 — P. 541 -544.
- Beom S.S. and Sun D.Y. Determination of Clopidogrel in human plasma by liguid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study // Biomed. Chromatogr.- 2007.-V.21.- P. 883−889.
- Bhatt D., Marso S., Hirsch A. et al. Amplified benefit of Clopidogrel versus aspirin in patients with diabetes mellitus.// Am J Cardiol. 2002. — V. 90 — P. 625 628.
- Boneu B., Desteile G. Platelet anti-aggregating activity and tolerance of Clopidogrel in atherosclerotic patients.// Thromb Haemost. 1996. — V.76 — P. 939−943.
- Brandt J.T., Close S.L., Itturia S.J. et all. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to Clopidogrel not prasugrel//Journal of Thrombosis and Hemostasis 2007. 5. — P. 2429−2436.
- Brandt J.T., Payne C.D., Wiviott S.D. et al. A comparison of prasugrel and Clopidogrel loading doses on platelet function: magnitude of platelet inhibition isrelated to active metabolite formation.//Amer.Heart J. 2007. — V.153, №l. -P.66−69.
- Braunwald E., Antman E.M., Beasley J.W. et al. ACC/AHA Guideline Update for the management of patients with unstable angina and non-ST elevation myocardial infraction-2002. Summary article.// Circulation. 2002. — V.106, № 14. — 1893 p.
- Brophy J.M., Babapulle M.N., Costa V., Rinfret S. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.//Am Heart J. 2006. — V.152, № 2. — P. 263−269.
- Caplain H., Donat F., Gaud C., Necciari J. Pharmacokinetics of clopidogrel.// Semin Thromb Hemost.- 1999.- V.25 suppl 2 P. 25−28.
- Carlo Patrono, Barry Coller, James E. Dalen et. al. Platelet-Active Drugs. The relationships Among Dose, Effectiveness, and Side Effects .//Chest. 2001. -V.119.-P. 39S-63S.
- Cattaneo M., Akkawat B., Lecehi A. et al. Tichlopidine selectively inhibits human platelet responses to adenosine diphosphate//Thromb. Haemost 1991.-V.66.-P.694−699.
- Chen K.W., Chow S.C., Li G/ A note on sample size determination for studies with high-order crossover designs.//J.Pharmacokinet.Biofarm. 1997. -Vol.25,No.6.-P.753−765.
- Chen M.L., Lee S.C., Ng M.J. et al Pharmacjkinetic analysis of bioeguivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics.//Clin.Pharmacol.Ther. 2000. — Vol.68, No5.- P.510−521.
- Chirhard M., Lalan Keraly, Delautier D. et al. Reduced sensitivity of human platelets to PAF-acether following tichlopidine intake.//Haemostasis 1989.-V.19-P.213−218.
- Clarke T.A., Waskell L.A. Clopidogrel is metabolized by human cytochrome P450 3A and inhibited by atorvastatin. Drug Metab. Dispos. 2003. — V.31, № 1.1091. P. 53−59.
- Coukell A.J., Markham A. Clopidogrel.// Drugs. 1997. — V.54 -P. 745−750.
- Daniel J., Dangelmaier C., Jin J. at al. Molecular basis for ADP-induced platelet activation: evidence for three distinct ADP receptors on human platelets.// J Biol Chem. 1998. — 273 — P.2024−2029.
- Darius H., Rupprecht H.J., Kreb P. et al. Accelerated inhibition of platelet activity by Clopidogrel loading dose in patients following coronory stent implantation//Eur. Heart J.- 1999. V.20. — P.252−254.
- Delea T.E., Edelsburg J.S., Richardson E. et al. Cost-effectivness of Clopidogrel in patients with ishemic stroke, myocardial infraction or peripheal arterial disease.// Value in Health. vol. 6 no. 3 may/june 2003 — p. 184−185.
- Denninger M.H., Necciari J., Serre-Lacroix E., Sissmann J. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis.// Semin Thromb Haemost. 1999.- 25, Suppl 2- P.41−50.
- Desager J.P. Clinical pharmacokinetics of ticlopidine.// Clin Pharmacokinet. -1994.-26-P. 347−355.
- Defreyn G., Gachet C., Savi P. et al. Ticlopidine abd Clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits.// Thromb Haemost. 1991. — V.765. — P.186−190.
- Diener H. C, Ringleb P.A., and Savi P. Clopidogrel for the secondary prevention of stroke//Expert Opinion n Pharmacotherapy. 2005. — 6. — P. 755−764.
- Farid N.A., Payne C.D., Small D.S. et al. Cytochrome P450 3A inhibition by ketaconazole affects prasugrel and Clopidogrel pharmacokinetics andpharmacodynamics differently .//Clin Pharmacol Ther. 2007. — V.81, № 5. — P. 735−741.
- Farid N.A., Kurihara A., Wrighton S.A. Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel and Prasugrel in Humans.//! of Clin.Pharmac. 2010. — V.50, No2. — P. 126−142
- Fontana P., Dupont A., Gandrille S. et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.// Circulation. 2003. — 108 — P.989−995.
- Foster C.J., Prosser D.M., Agans J.M. et al. Molecular indentification and characterization of the platelet ADP receptor targeted by thienoptridine antithrombotic drugs.// J Clin Invest. 2001. — 107 — P.1591−1598.
- Fox K.A. and Chelliah R. Clopidogrel: an updated and comprehensive review//Expert Opinion Drug Metabolism and Toxicology. 2007. — 3. — P. 621 631.
- Frelinger A.L. and Michelson A.D. Clopidogrel: Linking Evaluation of Platelet Response Variability to Mechanism of Action.// J. Am. Coll. Cardiol. -August 16, 2005.- 46(4) P. 646−647.
- Galteau M.M., Shamsa F. Urinary 6-beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.//Eur J Clin Pharmacol. 2003. — 59(10). — P. 713−733.
- Gawaz M., Ruf A., Neumann F.J. et al. Effect of glycoprotein Ilb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.// Thromb Haemost. 1998. — 80 — P.994−1001.
- Gerbel P.A., Bliden K.P., Hiatt B.L. et al. Clopidogrel for coronary stentingAresponse variability, dgur resistance and the effect of pretreatment platelet reactivity.// Circulation. 2003.- 107 — P.2908−2913.
- Gill S., Majumdar S., Brown N.E., Armstrong P.W. Ticlopidine -associated pancytopenia: implications of an acetylsalicylic acid alternative.// Can J Cardiol. -1997. 13 — P.909−913.
- Girolamo D., Czernuk P., Bertuola R., Keller G. Bioequivalence of Two Tablet Formulations of Clopidogrel in Healthy Argentinian volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study.//Clin.Therap. -2010. — V.32, No 1. -P.161−170.
- Gulec S., Ozdol C., Rahimov U. et al. Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-stain interaction.// J Invasive Cardiol. -2005.-17(11).-P. 589−593.
- Han Y.L., Li C.Y., Li Y. et al/ The antiplatelet effect of Clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting.//Zhonghua Xin Xue Guan Bing Za Zhi. 2007. -35(9).- P. 788−792.
- Hass W.K., Easton J.D., Adams H.P. et al/ A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in hight-risk patients: Ticlopidine Aspirin Stroke Study Group.// N Engl J Med. 1989. — 3 211 121. P. 501−507.
- Hechler B., Leon C., Vial C. et al. The P2Y1 receptor is necessary for adenosine 5 '-diphosphate-induced platelet aggregation.//Blood-1998.-92-P. 152−159/
- Heptinstall S., May J.A., Glenn J.R. et al. Effects of tichlopidine administered to healthy volunteers on platelet function in whole blood.//Thromb Haemost 1995.-V.74.-P.1310−1315.
- Hertbert J., Dol F., Bernat A. et al. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirine in several experimental odels in the rabbit.// Thromb Haemost. 1998. — 80 — P. 512−518.
- Herbert J.M., Savi J.P. Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist // Eur. Heart J.-1999-№ 1 (Suppl A).-A31-A-40.
- Jin J., Daniel J., Kunapuli S. Molecular basis for ADP induced platelet aggregation: the P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets.//J Biol Chem. 1998. — V.273-P.2030−2034.
- Jin J., Kunapuli S.P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.// Proc Natl Acad Sci USA. -1998. V.95 — P. 8070−8074.
- Kachhadia P.K., Doshi A.S., Joshi H.S. Validated Column High-Performance Liguid Chromatographic Method for Determination of Aspirin and Clopidigrel in Combined Tablets in the Presence of Degradation Product Formed Under ICH
- Recommended Stress Conditions.//! of AOAC International. 2009. — V.92, №l. -P.152−157.
- Kazui M., Ishizuka T., Yamamura A. et al. Mechanis of production of pharmacologically active metabolites of CS-747, a new pro-drug ADP-receptor antagonist.// XVIIIth Congress of the International Society of Thrombosis and Haemostasis.- 2001.- P.1916.
- Kolwankar D., Vuppalanchi R., Ethell B. et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity .//Clin Gastroenterol Hepatol. 2007. — V.5,N°3. — P. 388−393
- Ksycinska H., Rudski P., Bukowska-Kiliszek M. Determination of Clopidogrel metabolite (SR26334) in human plasms by LC-MS.// J Pharm Biomed Anal. -2006. V.41, № 2. — P. 533−9. .
- Lagorce P., Perez Y., Ortiz J. et al. Assay method for the carboxylic acid metabolite of Clopidogrel in human plasma by gas hromatography-mass spectrometry.// J Chromatogr B Biomed Sei Appl. 1998. — V.720, № 1−2. — P. 107−117.
- Lainesse A., Ozalp Y., Wong H. and Aplan R.S. Bioequivalence study of Clopidogrel bisulfate film-coated tablets//Arzneimittlforschung. — 2004. — 54. — P. 618−624.
- Lau W.C., Waskell L.A., Watkins P.B. et al. Atorvastatin reduces the ability of Clopidogrel to inhibit platelet aggregationA a new drug interaction. // Circulation. -2003. -V.107 — P.32−37.
- Lau W.C., Gurbek P.A., Watkins P.B. et all. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of Clopidogrel resistance.//Circulation. 2004. — 109, № 2. — P. 166−171.
- Lau W.C. and Gurbek P.A. Antiplatele drag resistance and drug-drug interactions: role of cytochrome P450 3A4//Pharmaceutical Research. — 2006. — 23.-P. 2691−2708/
- Leon C., Hechler B., Vial C., Leray C., Cazenave J.P., Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells.//FEBS Lett. 1997. -V. 403 -P.26−30.
- Lingpunsakul S., Kolwankar D., Pinto A., Gorski J.C., Hall S.D., Chalasani N. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics./ZHepatology. — 2005. — 41(5). P. 1144−1150.
- Mach F., Senouf D., Fontana P. et al. Not all sMins- htterfere with Clopidogrel during antiplatelet therapy.//Eur.J.Clin. Invest. 2005. — V.35. — P. 476−481.
- Mani H., Toennes S.W., Linnemann B. et al. Determination of Clopidogrel main metabolite in plasma: a useful tool for monitoring therapy?//Therapeutic Drug Monitoring 2008. — V.30. — P.84−89.
- Martin J. Quinn and Desmond J. Fitzgerald. Tclopidine and Clopidogrel// Circulation- 1999.-V. 100.-P.1667−1672.
- McEwen J., Strauch G., Perles P. et al/ Clopidogrel bioavailability: absence of influence of food or antacids.// Semin Thromb Hemost.- 1999.- V.25 suppl 2 P. 47−50.
- Meyers K. M, Holmsen H., Seachord C.L. Comparative study of platelet densegranule constituents. Am J Physiol. 1982.243: R454-R461.
- Minno G., Cerbone A.M., Mattioli P.L. et al. Functionally thrombathenic state in normal platelets following the administration of ticlopidine//J. Clin. Ivest. 1965-V.75-P.328−338.
- Mohan A., Hariharan M., Vikraman E. et al. Identification and characterization of a principal oxidation impurity in Clopidogrel drug substance and drug product.// J. of Pharmac. and Biomed. Anal. 2008. — V.47, №l. -P.183−189.
- Moliterno D.J., Topol E.J. Meta-analysis of platelet GP Ilb/IIIa antagonist randomized clinical trials in ischeic heart disease: consistent, durable salutary effects.// Circulation. 1997. — 96 (Suppl I) — P. 1−475.
- Moussa I., Oetgen M., Roubin G. et al. Effectiveness of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin in Preventing Stent Thrombosis After Coronary Stent Implantation.// Circulation. 1999. — 99 — P. 2364−2366.
- Muller I., Besta F., Schulz C. et al. Prevalence of Clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.// Thromb. Haemost. 2003. — V. 89 — P. 783−787.
- Neubauer H., Gunesdogan B., Hanefeld C. et al. Lipophilic statins interfere with the inhibitory effects of Clopidogrel on platelet function a flow cytometry study .//Eur Heart J. 2003. — V.24, № 19. — P.1744−1749.
- Nguyen T.A., Diodati J.G. and Pharand C. Resistance to Clopidogrel: A rewiew of the evidence.// J. Am. Coll. Cardiol. 2005. — V.45, № 8 — P. 11 571 164.
- Nirogi R.V.S., Kandikere V.N. and Mudigonda K. Effect of Food on
- Bioavailability of a Single Oral Dose of Clopidogrel in Healthy Male Subjects.//Arzneim.-Forsch./Drug Res. 2006. -V.56, Nol 1. — P.735−739.
- Pal D., Mitra A.K. MDR and CYP3A4-mediated drug-drug interactions.//! Neuroimmune Pharmacol. 2006. — V. l, № 3. — P. 323−339.
- Pereillo J-M., Maftouh M., Andrieu A. et al. Structure and Steriochrmistry of the Active Metabolite of Clopidogrel.// Drug Metabolism and Deposition.- 2002. -Vol.30, Issue 11. P.1288−1295.
- Piorkowsky M., Weikert U., Schwimmbeck P.L., Martus P., Schultheiss H.P., Rauch U. ADP induced platelet degranulation in healthy individuals is reduced by
- Clopidogrel after pretreatment with atorvastatin.//Thromb Haemost. -2004. 92(3). -P. 614−620.
- Rajput S.J., George R.K., Ruikar D.B. Chemometric Simultaneous Estimation of Clopidogrel Bisulphate and Aspirin from Combined Dosage Form.//Indian J. of Pharmaceut. Scinces. 2008. — V.70, No4. — P.450−454.
- Ramesh Mullangi and Nuggehally R.Srinivas. Clopidogrel: reviw of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies//Biomed.Chromatogr. 2009.-V.23.-P.26−41.
- Robinson A., Hills J., Neal C. and Leary A.C. The validation of a bioanalytical method for the determination of Clopidogrel in human plasma.// J. of Chromatography B. 2007. — V.848.- P.344.
- Rouini M.R., Ardakani Y.H., Foroumadi A et al. Sensitive Quantification of Carboxylic Acid Metabolite of Clopidogrel in Human Plasma by LS with UV Detection// Chromatographia. 2009. — V.70, № 5−6. — P.953−956.
- Quinn M.J., Fitzgerald D.J. Ticlopidine and Clopidogrel. Circulation — 1999. -V.1000. -P.1667−1672.
- Saber A.L., Elmosallamy M.A., Amin A.A. and Killa H.M.A. Liquid chromatographic and Potentiometrie method for determination of clopidogrel.//J. of Food and Druq Anal. 2008. — V.16, № 2. — P. l 1−18.
- Savcic M., Hauert J., Bachmann F. at al. Clopidogrel Dose Regimens: Kinetic Prifile of Pharmacodynamic Response in Healthy Subjects.//Semin Thromb Hemost-1999.-V.25.-P. 15−19.
- Savi P., Beauverger P., Labouret C. et all. Role of P2Y1 purinoreceptor in ADP-induced platelet activation.//FEBS Lett. 1998. — 422 — P.291−295.
- Savi P., Pereillo J.M., Uzabiaga F. et al Identification and biological activity of the active metabolite of Clopidogrel.// Thromb Haemostasis. 2000. -V.84 — P. 891−896.
- Savi P., Labouret C., Delesque N. et all. (2001) P2Y12, a new platelet ADP receptor, target of Clopidogrel.//Biophys Biochem Res Commun.- 2001. V.283 -P.379−383.
- Savi P. and Herbert J.M. Clopidogrel and ticlopedine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis//Seminars in Thrombosis and Haemostasis. — 2005. — 31.—P. 174−183.
- Saw J., Brennan D.M., Steinhubl S.R. et al/ CHARISMA Investigators. Lack of evidence of clopidogrel-statin interaction in the CHARISMA trial.//J Am Coll Cardiol. 2007. — 50(4). — P. 291−295.
- Shah J., Fratis A., Ellis D. et al. Effect of food and antacid on absorstion of orally administered ticlopidine hydrochloride.// J Clin Pharmacol. 1990. — V.30 -P.733−736.
- Shakeri-Nejad K., Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents.//Expert Opin Pharmacother. 2006. — 7(6). -P. 639−651.
- Shin B.S., Yoo S.D. Determination of Clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study .//Biomedical Chromatography. 2007. — V.21. -P.883−889.
- Singh S.S., Sharma K., Barot D. et al. Estimation of carboxylic acid metabolite of Clopidogrel in wistar rat plasma by HPLC and its application to pharmacokineticstudy.// J of Chromatogr. B. 2005. — V.821. — P.173.
- Sippel J., Sfaip L.L., Schapoval E.S., Steppe M. New high-performance liquid chromatographic method for determination of clopidogrel in coated tablets //J. of AOAC International. 2008. — V.91, №l. — P.67−72.
- Smith S.M., Judge H.M., Peters G., Storey R.F. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.//Platelets. 2004. — 15(8). — P. 465−474.
- Souri E., Jalalizadeh H., Kebriaee-Zadeh A. et al. Validated method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study.//Biomed. Chromatogr. 2006. — V.20. -P.1309−1314.
- Sugidachi A., Asai F., Ogawa T. et al The in vivo pharmacological profile of CS-747, a novel antiplatelet agent platelet ADP receptor antagonist properties.// B J Pharmacol. 2000, — 129 — P. 1439−1446.
- Sugidachi A., Asai F., Yoneda K. et al/ Antiplatelet action of R-99 224, an active metabolite of a novel thienopyridine-type Gi-linked antagonist, CS-747.// B J Pharmacol. -2001.-132- P.47−54.
- Sultana N., Arayne M.S., Nawas M., Ali K.A. Development and validation of liquid chromatographic method for the determination of clopidogrel from pharmaceutical dosage form.//J. of the Indian Chemical Society. 2009. — V.86, № 4. — P.406−409.
- Sun, B., Li J., Okahara K., Kambayashi J. P2X1 purinoreceptors in human platelets: molecular cloning and functional characterization after heterologous expression.// 1998.-V.273.-P.11 544−11 547.
- Takahashi M., Pang H., Kawabata K. et al. Quantitative determination of Clopidogrel active metabolite in human plasma by LC-MS/MS.// J. of Pharmac. And Biomed. Anal. 2008. — V.48, № 4. — P. 1219−1224.
- Taubert D., Kastrati A., Harlflnger S. et al. Pharmacokinetics of Clopidogrel after administration of a high loading dose.// Thrombosis and Haemostasis 2004. — V.92. -P.311−316.
- Taubert D., von Beckerath N., Grimberg G. et all. Impact of P-glycoprotein on Clopidogrel absorption//Clinical Pharmacology and Therapeutics. — 2006. 80. — P.486−501.
- Traub S.U., Johnson C.E. Comparison of methods of estimating creatinine clearance in children// Am.J.Hosp.Pharm.- 1980.-Vol.37.-P. 195−201.
- Vocilkova L., Opatrilova R., Sramek V. Determination of Clopidogrel by Chromatography .//Current Phamaceutical Analysis 2009. — V.5, No4. — P.424−431.
- Wada M., Nishiwaki J., Yamane T. et all. Interaction study of aspirin or Clopidogrel on pharmacokinetics of dopenezil hydrochloride in rats by HPLC-fluorescence detection/ZBiomedical Chromatography. 2007. — 21. — P. 616−620.
- Wang T.H., Bhatt D.L.and Topol E.J. Aspirin and Clopidogrel resistance: an emerging clinical entity.// Eur. Heart. J. March 2, 2006. — 27 (6) — P. 647−654.
- Wenaweser P., Windecker S., Billinger M. et al. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and Clopidogrel treatment in patients with coronary stent thrombosis.//Am J Cardiol. 2007. — 99(3). — P. 353−356.
- Wildt S.N., Berns M.J., van der Anker J.N. 13C-erythromycin breath test as a noninvasive measure of CYP3A activity in newborn infants: a pilot study.//Ther-Drug Monit. 2007. — 29(2). — P. 225−230.
- Yang X.L., Liu S.Q., Sun J. Et al. UPLC for the Determination of Clopidogrel in Dog Plasma by Tandem Quadrupole MS: Application to a Pharmacokinetic Study.//Chromatographia 2009. — V.70, № 1−2. — P.259−263.
- Yim H.B., Lieu P.K., Choo P.W. Ticlopidine induced cholestatic jaundice.// Singapore Med J. 1997. — 38 — P. 132−133.
- Yousef A.M., Arafat T., Bulatova N.R. and Al-Zumyli R. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel//Journal of Clinical Pharmacology and Therapeutics. 2008. — 33. — P. 439−449.
- Zhou S.F., Xue C.C., Yu X.Q., Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update.//Curr Drug Metab. 2007. — 8(6). — P. 526−553.